Authors
Latest:
Dr Chon on Durvalumab Plus Chemotherapy and Olaparib in Endometrial CancerHye Sook Chon, MD, discusses the DUO-E trial of frontline durvalumab plus chemotherapy followed by durvalumab and olaparib in endometrial cancer.
Latest:
Dr. Muss on the Use of Metronomic Chemotherapy in Metastatic Breast CancerHyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.
Latest:
Dr. Chung on the Rationale of the KEYNOTE-811 Trial in HER2+ Gastric CancerHyun C. Chung, MD, PhD, discusses the rationale of the KEYNOTE-811 study in HER2-positive gastric cancer.
Latest:
Dr. Kim on Combining Immunotherapy and TKIs in Metastatic RCCHyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the potential combination of immunotherapy and tyrosine kinase inhibitors in metastatic renal cell carcinoma.
Latest:
Dr. Bowman on Rationale for Radio-Labeled Atezolizumab PET/CT Scans in RCCI. Alex Bowman, MD, discusses the rationale for an exploratory clinical trial of radio-labeled 89Zr-atezolizumab PET/CT scans in renal cell carcinoma.
Latest:
Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced PatientsA mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.
Latest:
Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ CancerIan Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.
Latest:
Dr. Davis on the ANZUP Collaboration on the ENZAMET Trial in Prostate CancerIan Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaboration on the randomizedphase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.
Latest:
Dr Krop on Age-Related Survival Outcomes With T-DXd in HER2+ Breast CancerIan E. Krop, MD, PhD, discusses the use of fam-trastuzumab deruxtecan-nxki across age groups in the DESTINY Breast trials in patients with HER2-positive metastatic breast cancer.
Latest:
Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular LymphomaIan Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.
Latest:
Dr. Flinn on the FDA Approval of Zanubrutinib in CLL/SLLIan Flinn, MD, PhD, discusses the significance of the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Latest:
Case Discussion: 68-Year-Old With R/R Follicular LymphomaA panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.
Latest:
Novel Therapies for R/R Follicular LymphomaA panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.
Latest:
Dr. Ganly on a Postoperative Nomogram for Predicting Cancer-Specific Mortality in MTCIan Ganly, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in MTC.
Latest:
Making a Differential Diagnosis of Low-Grade Serous Ovarian CancerExpert oncologist Ian Hagemann, MD, PhD, shares insight into the process of making a differential diagnosis of low-grade serous ovarian cancer in light of adjacent disease and available IHC testing.
Latest:
Dr. Thompson on Prostate Biopsy Problems and SolutionsIan M. Thompson, MD, director, professor, Department of Urology, Cancer Therapy & Research Center, The University of Texas Health Science Center, discusses the problems with prostate biopsies and some possible solutions.
Latest:
Clinical Pearls in the Management of Marginal Zone LymphomaClosing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.
Latest:
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in CareClosing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
Latest:
Dr. Alshaygy on Precision Medicine Research in TGCTIbrahim S. Alshaygy, MD, MSC, discusses precision medicine research in tenosynovial giant cell tumor.
Latest:
Dr Garrido-Laguna on the Mechanism of Action of RMC-6236 in KRAS-Mutant PDACIgnacio Garrido-Laguna, MD, PhD, MBA, discusses preliminary safety and efficacy data with the use of RMC-6236 in patients with KRAS-mutated pancreatic ductal adenocarcinoma, highlighting the ongoing investigation of this agent.
Latest:
Exciting NSCLC Data Updates from ESMO 2022The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.
Latest:
Should You Take a Break After Your Oncology Fellowship?The question of what to do between completing a fellowship and starting a new job is a big one.
Latest:
Dr. Puzanov on Management of Adverse Events in MelanomaIgor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses ways to manage patients with melanoma who may experience adverse events in response to treatment with immunotherapy.
Latest:
Tackling the Adverse Effects of ImmunotherapyIgor Puzanov, MD, MSCI, FACP, discusses the adverse effects associated with immunotherapy and how to manage them.
